This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 9 of 15 for:    lupus | Recruiting, Not yet recruiting, Available Studies | United States, Kansas | United States, Michigan | United States, Minnesota

Aurinia Renal Response in Active Lupus With Voclosporin (AURORA)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Aurinia Pharmaceuticals Inc.
Sponsor:
Information provided by (Responsible Party):
Aurinia Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT03021499
First received: January 12, 2017
Last updated: June 9, 2017
Last verified: June 2017
  Purpose
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.

Condition Intervention Phase
Lupus Nephritis Drug: Voclosporin Drug: Placebo Oral Capsule Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Resource links provided by NLM:


Further study details as provided by Aurinia Pharmaceuticals Inc.:

Primary Outcome Measures:
  • The number of subjects achieving renal response [ Time Frame: 52 Weeks ]
    The number of subjects achieving renal response


Secondary Outcome Measures:
  • Time to UPCR of ≤0.5 mg/mg. [ Time Frame: 52 Weeks ]
    Time to UPCR of ≤0.5 mg/mg.

  • Partial renal response [ Time Frame: Weeks 24 and 52 ]
    Partial renal response

  • Time to 50% reduction in UPCR from baseline. [ Time Frame: 52 Weeks ]
    Time to 50% reduction in UPCR from baseline.

  • Renal response at Week 52 [ Time Frame: 52 Weeks ]
    Renal response at Week 52

  • Duration of renal response [ Time Frame: 52 Weeks ]
    Duration of renal response

  • Change from baseline in laboratory parameters at each time point [ Time Frame: 52 Weeks ]
    Change from baseline in laboratory parameters at each time point

  • Renal response with low-dose steroids [ Time Frame: 52 Weeks ]
    Renal response with low-dose steroids

  • Quality of Life questionnaires [ Time Frame: Weeks 12, 24 and 52 ]
    Quality of Life questionnaires

  • Change from baseline in the SELENA-SLEDAI Index score [ Time Frame: Weeks 24 and 52 ]
    Change from baseline in the SELENA-SLEDAI Index score


Estimated Enrollment: 324
Actual Study Start Date: May 17, 2017
Estimated Study Completion Date: March 2020
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Voclosporin
oral, 23.7 mg BID
Drug: Voclosporin
calcineurin inhibitor
Other Name: ISA247
Placebo Comparator: Placebo Oral Capsule
Voclosporin placebo, oral, 3 capsules BID
Drug: Placebo Oral Capsule
matching placebo capsule

Detailed Description:
The aim of the current study is to investigate whether voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 52 weeks. The background therapy will be MMF and initial treatment with IV methylprednisolone, followed by a reducing course of oral corticosteroids. Subjects with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria (as measured by urine protein/creatinine ratio (UPCR) while demonstrating an acceptable safety profile.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

- Subjects with evidence of active nephritis, defined as follows:

  • Kidney biopsy result within 2 years prior to screening indicating Class III, IV-S, IV-G (alone or in combination with Class V), or Class V LN with a doubling or greater increase of UPCR within the last 6 months to a minimum of ≥1.5 mg/mg for Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy results over 6 months prior to screening must be reviewed with a medical monitor to confirm eligibility.

OR

  • Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S or IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at screening.

OR

  • Kidney biopsy result within 6 months prior to screening indicating Class V LN and a UPCR of ≥2 mg/mg at screening.

    • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.

Exclusion Criteria:

  • Estimated glomerular filtration rate (eGFR) of ≤45 mL/minute at screening.
  • Current or medical history of:

    • Congenital or acquired immunodeficiency.
    • In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.
    • Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.
    • Lymphoproliferative disease or previous total lymphoid irradiation.
    • Severe viral infection or known HIV infection.
    • Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
  • Other known clinically significant active medical conditions, such as:

    • Severe cardiovascular disease, liver dysfunction or chronic obstructive pulmonary disease or asthma requiring oral steroids or any other overlapping autoimmune condition for which the condition or the treatment of the condition may affect the study assessments or outcomes.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03021499

Contacts
Contact: Robert Huizinga 250 708 4322 rhuizinga@auriniapharma.com
Contact: Rashieda Gluck rgluck@auriniapharma.com

Locations
United States, California
AURORA Investigative Center Recruiting
Los Angeles, California, United States, 90024
AURORA Investigative Center Recruiting
Thousand Oaks, California, United States, 91360
United States, Colorado
AURORA Investigative Center Recruiting
Denver, Colorado, United States, 80218
United States, Florida
AURORA Investigative Center Recruiting
Miami, Florida, United States, 33126
United States, Michigan
AURORA Investigative Center Recruiting
Grand Blanc, Michigan, United States, 48439
United States, Nevada
AURORA Investigative Center Recruiting
Las Vegas, Nevada, United States, 89128
United States, North Carolina
AURORA Investigative Center Recruiting
Chapel Hill, North Carolina, United States, 27514
AURORA Investigative Center Recruiting
Charlotte, North Carolina, United States, 28210
AURORA Investigative Center Recruiting
Greenville, North Carolina, United States, 27834
AURORA Investigative Center Recruiting
New Bern, North Carolina, United States, 28562
AURORA Investigative Center Recruiting
Raleigh, North Carolina, United States, 27617
United States, Ohio
AURORA Investigative Center Recruiting
Columbus, Ohio, United States, 43210
United States, Oklahoma
AURORA Investigative Center Recruiting
Oklahoma City, Oklahoma, United States, 73103
AURORA Investigative Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Costa Rica
AURORA Investigative Center Recruiting
San José, Costa Rica
Dominican Republic
AURORA Investigative Center Recruiting
Santiago de los Caballeros, Dominican Republic
Malaysia
AURORA Investigative Center Recruiting
George Town, Malaysia
Puerto Rico
AURORA Investigative Center Recruiting
San Juan, Puerto Rico
Sponsors and Collaborators
Aurinia Pharmaceuticals Inc.
Investigators
Principal Investigator: Mary Anne Dooley, MD, MPH University of North Carolina
  More Information

Publications:

Responsible Party: Aurinia Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03021499     History of Changes
Other Study ID Numbers: AUR-VCS-2016-01
Study First Received: January 12, 2017
Last Updated: June 9, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Aurinia Pharmaceuticals Inc.:
lupus nephritis
calcineurin inhibitors
voclosporin

Additional relevant MeSH terms:
Lupus Nephritis
Lupus Erythematosus, Systemic
Nephritis
Glomerulonephritis
Kidney Diseases
Urologic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Calcineurin Inhibitors
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on June 29, 2017